logo
Share SHARE
FONT-SIZE Plus   Neg

Santarus NDA For Inflammatory Bowel Disease Therapy Uceris Accepted By FDA

Santarus Inc. (SNTS: Quote) Wednesday reported that the United States Food and Drug Administration, or FDA, accepted for filing its New Drug Application, or NDA, seeking approval to market Uceris tablets as a therapy to induce remission of mild to moderate active ulcerative colitis. The company anticipates the completion of the FDA's review by mid-October 2012.

The NDA seeks to market Uceris in a 9 milligram, or mg, tablet. Also, Cosmo Pharmaceuticals SpA-owned Cosmo Technologies Ltd., a collaborator in the development of Uceris, is now eligible to $4 million in cash or stock as a milestone payment, Santarus Said.

A form of inflammatory bowel disease, or IBD, ulcerative colitis can cause inflammations and ulcers along the colon, resulting in such effects as diarrhea, frequent bowel movements and bleeding. About 1.4 million Americans suffer from IBDs. Uceris is the trade name for budesonide, which is a corticosteroid with topical anti-inflammatory properties.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Warner Bros. Interactive Entertainment said its upcoming mobile game releases in 2015 would include Batman, DC Comics, LEGO, "Game of Thrones," and "Mortal Combat X". A study claims the ghastly civil war in Syria is the result of a severe drought brought about by global warming - in what is yet the strongest link between climate change and armed conflict. U.S. electronics giant Apple Inc. (AAPL) regained the top spot in the world smartphone market from South Korea's Samsung Electronics Co Ltd. after a gap of three years, according to a report released Tuesday by market research firm Gartner, Inc. (IT). Apple sold 74.832 million smartphones in the...
comments powered by Disqus
Follow RTT